

Epidemic Pertussis and Acellular Pertussis Vaccine Failure in the 21st Century

James D. Cherry, MD, MSc

In this issue of *Pediatrics* Acosta et al¹ present a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) vaccine effectiveness study in adolescents in Washington State during the first 6 months of 2012. Their findings support the previous Tdap effectiveness data from Wisconsin.² The duration of Tdap effectiveness is disappointing, particularly because case-control studies tend to inflate efficacy.³

In 4 recent publications (including 1 article in *Pediatrics*) I have discussed epidemic pertussis and why vaccines fail.⁴⁻⁷ Before discussing why Tdap vaccine effectiveness wanes so rapidly, it seems worthwhile to discuss how rapidly protection wanes after a natural infection in the pre-Tdap era and to take a realistic look at the resurgence of pertussis.

The resurgence of pertussis is often attributed to the switch from whole-cell pertussis vaccines to acellular products. However, the increase in reported pertussis began ~14 years before the universal use of diphtheria-tetanus-acellular pertussis (DTaP) vaccines in childhood commenced. The 2 greatest contributors to the resurgence of pertussis are greater awareness and more sensitive diagnosis (the routine use of polymerase chain reaction).⁴⁻⁷

In the pre-DTaP and -Tdap eras, the pertussis attack rate in non-epidemic periods in largely whole-cell pertussis vaccine-primed adolescents and adults was 370 to 500 per 100 000 per year.^{8,9} These rates are underestimates

because of clear evidence of “observer bias” in both studies.¹⁰ In this present Washington State study, which involved adolescents 11 to 18 years of age, 81% of whom had received Tdap vaccines, the attack rate during the epidemic was only 182.3 per 100 000 for the one-half-year study period.¹ This rate is no greater than that noted during non-epidemic periods in the pre-DTaP and -Tdap eras.^{8,9}

In 2012 in *Pediatrics* I discussed why pertussis vaccines fail⁴; however, new data have become available over the past 2 years. Of the 7 vaccine efficacy trials in the 1990s, in which diphtheria-tetanus toxoids-pertussis (DTP) vaccine efficacy was compared with DTaP vaccine efficacy, 5 different DTP vaccines were used. In 5 trials 4 different DTP vaccines from different manufacturers were more effective than the DTaP vaccines they were compared with. The only exception was 1 lot of US Connaught DTP vaccine, which was used in 2 trials; it was chosen because of its known low reactogenicity, but it was subsequently shown to lack immunogenicity and it had poor efficacy.

Factors that I think are most important relating to DTaP vaccine failure are as follows: decay in antibody over time; a T helper (Th) 1/Th2 versus a Th1, Th17 cellular response; incomplete antigen package; incorrect balance of antigens in the vaccine; linked-epitope suppression; and the occurrence of pertactin-deficient *Bordetella pertussis* strains.^{4,11-18} Some, but not all, of these factors may also relate to Tdap failure over time.

Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California

Opinions expressed in these commentaries are those of the author and not necessarily those of the American Academy of Pediatrics or its Committees.

www.pediatrics.org/cgi/doi/10.1542/peds.2014-4118

DOI: 10.1542/peds.2014-4118

Accepted for publication Mar 16, 2015

Address correspondence to James D. Cherry, MD, MSc, Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, MDCC 22-442, Los Angeles, CA 90095-1972. E-mail: jcherry@medent.ucla.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2015 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The author has indicated he has no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: Dr Cherry is a member of the Sanofi Pasteur Speaker's Bureau. He is also a member of the Global Pertussis Initiative which is supported by Sanofi Pasteur. He receives royalties from Elsevier for *Feigin and Cherry's Textbook of Pediatric Infectious Diseases*.

COMPANION PAPER: A companion to this article can be found on page XXX, online at www.pediatrics.org/cgi/doi/10.1542/peds.2014-3358.

In contrast to children in whom antibody decay after vaccination (with both DTP and DTaP) or infection is relatively rapid, the antibody pattern in adolescents and adults is different.^{19–23} In adolescents and adults after infection or vaccination the antibody values to pertactin, filamentous hemagglutinin (FHA), and fimbriae persist for a prolonged period, whereas antibody to pertussis toxin declines relatively rapidly.^{21–23}

This fact, as noted in the Adult Acellular Pertussis Vaccine Efficacy Trial (APERT) trial, led us to predict that an every-10-year booster program (if universally applied) could decrease the circulation of *B pertussis*.²³

So why was our prediction that a 10-year booster would decrease the incidence and prevalence of pertussis wrong? In the microbiologic world there are a number of organisms that contain proteins similar to FHA, pertactin, and fimbriae.²⁴ In contrast, the only organism that has pertussis toxin is *B pertussis*. The persistence of antibody to FHA, pertactin, and fimbriae may be due to cross-reacting epitopes from other organisms, which our enzyme-linked immunosorbent assay picks up.⁴ However, it seems apparent that the antibody values that we have determined do not offer much protection against *B pertussis* cough illness in adolescents and adults.

Although adequate data are presently not available, it can be assumed that adolescents and adults who were primed in infancy by infection or DTP will have a Th1, Th17 response to Tdap. In contrast, those who were primed by DTaP will have a Th1/Th2 response.

In line with the results of these 2 recent Tdap effectiveness studies, we should examine our present Tdap immunization recommendations. It is my opinion that we should continue with our present Tdap schedules. Of most importance is to see that all pregnant women receive Tdap with each pregnancy.^{25,26} This alone can prevent virtually all pertussis deaths in young infants.

REFERENCES

- Acosta A, Debolt C, Tasslimi A, et al. Tdap vaccine effectiveness among adolescents during the 2012 Washington State pertussis epidemic. *Pediatrics*. 2015
- Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. *J Infect Dis*. 2014;210(6):942–953
- Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. *Rev Infect Dis*. 1987;9(5):866–883
- Cherry JD. Why do pertussis vaccines fail? *Pediatrics*. 2012;129(5):968–970
- Cherry JD. Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease. *N Engl J Med*. 2012;367(9):785–787
- Cherry JD. Pertussis: challenges today and for the future. *PLoS Pathog*. 2013;9(7):1–3
- Cherry JD. The present and future control of pertussis. *Clin Infect Dis*. 2010;51(6):663–667
- Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. *J Infect Dis*. 2001;183(9):1353–1359
- Ward JI, Cherry JD, Chang SJ, et al; APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med*. 2005;353(15):1555–1563
- Cherry JD, Heininger U, Stehr K, Christenson P. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. *Pediatrics*. 1998;102(4 pt 1):909–912
- Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. *Proc Natl Acad Sci USA*. 2014;111(2):787–792
- Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. *Mucosal Immunol*. 2013;6(4):787–796
- Cherry JD, Heininger U, Richards DM, et al. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. *Clin Vaccine Immunol*. 2010;17(5):741–747
- Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. *Vaccine*. 1998;16(20):1907–1916
- Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. *Vaccine*. 1998;16(20):1901–1906
- Pawloski LC, Queenan AM, Cassidy PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. *Clin Vaccine Immunol*. 2014;21(2):119–125
- Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. *JAMA*. 2012;308(5):454–456
- Cherry JD, Olin P. The science and fiction of pertussis vaccines. *Pediatrics*. 1999;104(6):1381–1383
- Blumberg DA, Mink CM, Cherry JD, et al. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. *J Pediatr*. 1990;117(1 pt 1):46–51
- Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR; Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. *Pediatrics*. 2009;123(1):301–312
- Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. *Clin Infect Dis*. 2004;38(4):591–594
- Hodder SL, Cherry JD, Mortimer EA Jr, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. *Clin Infect Dis*. 2000;31(1):7–14

23. Le T, Cherry JD, Chang SJ, et al; APERT Study. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. *J Infect Dis.* 2004;190(3):535–544
24. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. *Clin Microbiol Rev.* 2005;18(2):326–382
25. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. *Clin Infect Dis.* 2015;60(3):333–337
26. Cherry JD. Tetanus-diphtheria-pertussis immunization in pregnant women and the prevention of pertussis in young infants. *Clin Infect Dis.* 2015;60(3):338–340

Epidemic Pertussis and Acellular Pertussis Vaccine Failure in the 21st Century

James D. Cherry

Pediatrics originally published online May 4, 2015;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/early/2015/04/28/peds.2014-4118.citation>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Epidemic Pertussis and Acellular Pertussis Vaccine Failure in the 21st Century

James D. Cherry

Pediatrics originally published online May 4, 2015;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/early/2015/04/28/peds.2014-4118.citation>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2015 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

